Merck licenses ovarian cancer candidate to AstraZeneca

AstraZeneca secured the rights to develop, produce and commercialize Merck & Co.'s experimental drug MK-1775, which is in midstage trials for ovarian cancer. The deal entitles Merck to $50 million upfront, potential milestone fees and sales royalties. "The compound has demonstrated encouraging clinical efficacy data, and we intend to study it in a range of cancer types where there is a high unmet medical need," said Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC